RIPK1 activation in Mecp2-deficient microglia promotes inflammation and glutamate release in RTT.

Rett syndrome (RTT) is a devastating neurodevelopmental disorder primarily caused by mutations in the methyl-CpG binding protein 2 (Mecp2) gene. Here, we found that inhibition of Receptor-Interacting Serine/Threonine-Protein Kinase 1 (RIPK1) kinase ameliorated progression of motor dysfunction after onset and prolonged the survival of Mecp2-null mice. Microglia were activated early in myeloid Mecp2-deficient mice, which was inhibited upon inactivation of RIPK1 kinase. RIPK1 inhibition in Mecp2-deficient microglia reduced oxidative stress, cytokines production and induction of SLC7A11, SLC38A1, and GLS, which mediate the release of glutamate. Mecp2-deficient microglia release high levels of glutamate to impair glutamate-mediated excitatory neurotransmission and promote increased levels of GluA1 and GluA2/3 proteins in vivo, which was reduced upon RIPK1 inhibition. Thus, activation of RIPK1 kinase in Mecp2-deficient microglia may be involved both in the onset and progression of RTT.

Citation

Ze Cao, Xia Min, Xingxing Xie, Maoqing Huang, Yingying Liu, Weimin Sun, Guifang Xu, Miao He, Kaiwen He, Ying Li, Junying Yuan. RIPK1 activation in Mecp2-deficient microglia promotes inflammation and glutamate release in RTT. Proceedings of the National Academy of Sciences of the United States of America. 2024 Feb 06;121(6):e2320383121

Mesh Tags

Substances

PMID: 38289948

search → result